Skip to content

Study · Not a test of the peptide alone · 2017

8 results

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.

Harris SB, Kocsis G, Prager R, Ridge T, Chandarana K, Halladin N, Jabbour S

Diabetes, obesity & metabolism3 Mar 2017Cited by 50 (Europe PMC)

PMID28124817 (opens in a new tab)PMCIDPMC5484356 (opens in a new tab)DOI10.1111/dom.12892 (opens in a new tab)PepBankPUB-28124817
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on oral drugs, IDegLira lowered mean HbA1c from 8.2% to 6.1% with once-weekly titration and from 8.1% to 6.0% with twice-weekly titration.

    In plain wordsIn adults with type 2 diabetes, the insulin and liraglutide combination lowered average HbA1c with both titration schedules.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change at week 32
    Study

    n = 420

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c
    8.2%
    once-weekly, baseline
    HbA1c
    6.1%
    once-weekly, week 32
    HbA1c
    8.1%
    twice-weekly, baseline
    HbA1c
    6%
    twice-weekly, week 32

    Source sentences

    Summary
    Mean HbA1c decreased from 8.2% (65 mmol/mol) to 6.1% (43 mmol/mol) with once-weekly titration and from 8.1% (65 mmol/mol) to 6.0% (42 mmol/mol) with twice-weekly titration
    1 context sentence
    Summary · context
    This 32-week, open-label, non-inferiority trial randomized adults with type 2 diabetes uncontrolled on metformin ± pioglitazone to receive IDegLira, titrated either once weekly, based on the mean of 2 pre-breakfast plasma glucose (PG) readings (n = 210), or twice weekly, based on the mean of 3 pre-b…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, once-weekly titration of IDegLira was non-inferior to twice-weekly titration for HbA1c.

    In plain wordsIn adults with type 2 diabetes, adjusting the combination once a week worked as well for HbA1c as adjusting twice a week.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c non-inferiority of once-weekly versus twice-weekly titration
    Study

    n = 420

    Comparator
    IDegLira titrated twice weekly
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Estimated treatment difference
    0.12%
    once vs twice weekly

    Source sentences

    Summary
    non-inferiority was confirmed (estimated treatment difference: 0.12% [-0.04; 0.28]95%CI , 1.30 mmol/mol [-0.41; 3.01]95%CI ).
    1 context sentence
    Summary · context
    This 32-week, open-label, non-inferiority trial randomized adults with type 2 diabetes uncontrolled on metformin ± pioglitazone to receive IDegLira, titrated either once weekly, based on the mean of 2 pre-breakfast plasma glucose (PG) readings (n = 210), or twice weekly, based on the mean of 3 pre-b…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, about 90% of patients reached HbA1c below 7% in each IDegLira titration arm.

    In plain wordsIn adults with type 2 diabetes, about 90 out of 100 patients reached HbA1c below 7% with either titration schedule.

    Peptide
    Liraglutide
    Outcome
    No significant changePatients reaching HbA1c below 7%
    Study

    n = 420

    Comparator
    IDegLira titrated twice weekly
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Patients with HbA1c <7%
    ≈ 90%
    each arm

    Source sentences

    Summary
    Approximately 90% of patients achieved HbA1c < 7% in each arm.
    1 context sentence
    Summary · context
    This 32-week, open-label, non-inferiority trial randomized adults with type 2 diabetes uncontrolled on metformin ± pioglitazone to receive IDegLira, titrated either once weekly, based on the mean of 2 pre-breakfast plasma glucose (PG) readings (n = 210), or twice weekly, based on the mean of 3 pre-b…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, mean fasting plasma glucose was similar after 32 weeks with once-weekly and twice-weekly IDegLira titration.

    In plain wordsIn adults with type 2 diabetes, fasting blood sugar was similar with both titration schedules of the insulin and liraglutide combination.

    Peptide
    Liraglutide
    Outcome
    No significant changeFasting plasma glucose at week 32
    Study

    n = 420

    Comparator
    IDegLira titrated twice weekly
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Mean fasting PG was similar after 32 weeks.
    1 context sentence
    Summary · context
    This 32-week, open-label, non-inferiority trial randomized adults with type 2 diabetes uncontrolled on metformin ± pioglitazone to receive IDegLira, titrated either once weekly, based on the mean of 2 pre-breakfast plasma glucose (PG) readings (n = 210), or twice weekly, based on the mean of 3 pre-b…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, IDegLira weight change was -1.0 kg with once-weekly titration and -2.0 kg with twice-weekly titration.

    In plain wordsIn adults with type 2 diabetes, weight fell by 1.0 kg with weekly and 2.0 kg with twice-weekly adjustment of the combination.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight change
    Study

    n = 420

    Comparator
    IDegLira titrated twice weekly
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    −1 kg
    once-weekly titration
    Weight change
    −2 kg
    twice-weekly titration

    Source sentences

    Summary
    Weight change was -1.0 kg vs -2.0 kg for once-weekly vs twice-weekly titration.
    1 context sentence
    Summary · context
    This 32-week, open-label, non-inferiority trial randomized adults with type 2 diabetes uncontrolled on metformin ± pioglitazone to receive IDegLira, titrated either once weekly, based on the mean of 2 pre-breakfast plasma glucose (PG) readings (n = 210), or twice weekly, based on the mean of 3 pre-b…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, rates of severe or confirmed symptomatic hypoglycaemia with IDegLira were low in both arms.

    In plain wordsIn adults with type 2 diabetes, low blood sugar events were rare with both titration schedules of the combination.

    Peptide
    Liraglutide
    Outcome
    Not applicableSevere or confirmed symptomatic hypoglycaemia rate
    Study

    n = 420

    Comparator
    IDegLira titrated twice weekly
    Outcome group
    Adverse events · Metabolic and weight

    Measurements

    Hypoglycaemia rate
    0.16 events/PYE
    once-weekly titration
    Hypoglycaemia rate
    0.76 events/PYE
    twice-weekly titration

    Source sentences

    Summary
    Rates of severe or blood glucose-confirmed symptomatic hypoglycaemia were low in both arms: 0.16 events/patient-year of exposure (PYE) for once-weekly, 0.76 events/PYE for twice-weekly titration.
    1 context sentence
    Summary · context
    This 32-week, open-label, non-inferiority trial randomized adults with type 2 diabetes uncontrolled on metformin ± pioglitazone to receive IDegLira, titrated either once weekly, based on the mean of 2 pre-breakfast plasma glucose (PG) readings (n = 210), or twice weekly, based on the mean of 3 pre-b…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 07HumanNot a test of Liraglutide aloneRandomized controlled trialOther

    In adults with type 2 diabetes, the mean IDegLira dose at 32 weeks was 41 dose steps in both arms.

    In plain wordsIn adults with type 2 diabetes, the average dose of the combination after 32 weeks was the same in both arms.

    Peptide
    Liraglutide
    Outcome
    Not applicableMean IDegLira dose at week 32
    Study

    n = 420

    Comparator
    IDegLira titrated twice weekly
    Outcome group
    Patterns of use · Pharmacology

    Measurements

    Mean IDegLira dose
    41 dose steps
    both arms

    Source sentences

    Summary
    Mean IDegLira dose at 32 weeks was 41 dose steps (41 U IDeg/1.48 mg Lira) for both arms.
    1 context sentence
    Summary · context
    This 32-week, open-label, non-inferiority trial randomized adults with type 2 diabetes uncontrolled on metformin ± pioglitazone to receive IDegLira, titrated either once weekly, based on the mean of 2 pre-breakfast plasma glucose (PG) readings (n = 210), or twice weekly, based on the mean of 3 pre-b…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 08HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, overall adverse event rates with IDegLira were 207.8 and 241.3 events per 100 patient-years with once-weekly and twice-weekly titration.

    In plain wordsIn adults with type 2 diabetes, side effect rates of the combination were 207.8 and 241.3 events per 100 patient-years with weekly and twice-weekly adjustment.

    Peptide
    Liraglutide
    Outcome
    Not applicableOverall adverse event rate
    Study

    n = 420

    Comparator
    IDegLira titrated twice weekly
    Outcome group
    Adverse events · Whole body

    Measurements

    Adverse event rate
    207.8 events/100 PYE
    once-weekly titration
    Adverse event rate
    241.3 events/100 PYE
    twice-weekly titration

    Source sentences

    Summary
    Overall adverse event rates were 207.8 and 241.3 events/100 PYE with once-weekly and twice-weekly titration, respectively.
    1 context sentence
    Summary · context
    This 32-week, open-label, non-inferiority trial randomized adults with type 2 diabetes uncontrolled on metformin ± pioglitazone to receive IDegLira, titrated either once weekly, based on the mean of 2 pre-breakfast plasma glucose (PG) readings (n = 210), or twice weekly, based on the mean of 3 pre-b…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02298192

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

Novo Nordisk A/Sn = 42021 Nov 2014 to 23 Dec 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 23 May 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.